1. Volume 144, Issue 3, Pages 990-998 (September 2013)
Incidence and Risk Factors of Legionella pneumophila Pneumonia During Anti-Tumor Necrosis Factor Therapy 
Fanny Lanternier, MD, Florence Tubach, MD, PhD, Philppe Ravaud, MD, PhD, Dominique Salmon, MD, PhD, Pierre Dellamonica, MD, PhD, Stephane Bretagne, MD, PhD, Marie Couret, MD, Beatrice Bouvard, MD, Michel Debandt, MD, Isabelle Gueit, MD, Jean-Pierre Gendre, MD, Jean Leone, MD, Nathalie Nicolas, MD, Dider Che, PharmD, MPH, Xavier Mariette, MD, PhD, Olivier Lortholary, MD, PhD 
CHEST 
Volume 144, Issue 3, Pages (September 2013)
DOI: /chest
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Sensitivity analysis of the results of the incidence study: SIRs for Legionella pneumophila pneumonia (per 100,000 patient-years) with 95% CIs, for all anti-TNF-α agents, according to the last anti-TNF-α agent received and each drug in patients who received only one anti-TNF-α agent. The plot size relates to the number of patients treated in the calculation (denominator of the incidence rate). n = number of cases of legionellosis observed in each category; SIR = standardized incidence ratio; TNF = tumor necrosis factor.
CHEST  , DOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

3. Figure 2
Sensitivity analysis of the results of the case-control analysis: ORs with 95% CIs, from multivariable analysis for the risk of Legionella pneumophila pneumonia when treated with adalimumab or infliximab rather than with etanercept. n: number of cases involved in the case-control model (four control subjects per case in the model). The plot size relates to the number of cases in the case-control analysis (n). See Figure 1 legend for expansion of other abbreviation.
CHEST  , DOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions